INT26702

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.70
First Reported 1989
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 17
Total Number 17
Disease Relevance 3.56
Pain Relevance 3.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (CD36) transport (CD36) small molecule metabolic process (CD36)
cell adhesion (CD36) Golgi apparatus (CD36) plasma membrane (CD36)
Anatomy Link Frequency
adipocytes 2
macrophages 1
monocytes 1
CD36 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 18 100.00 Very High Very High Very High
Adalimumab 1095 99.92 Very High Very High Very High
cytokine 105 99.12 Very High Very High Very High
Potency 3 97.88 Very High Very High Very High
Inflammation 287 96.40 Very High Very High Very High
Clonidine 1 92.80 High High
adenocard 1 88.80 High High
agonist 4 87.48 High High
aspirin 45 83.72 Quite High
dexamethasone 30 82.48 Quite High
Disease Link Frequency Relevance Heat
Obesity 39 100.00 Very High Very High Very High
INFLAMMATION 335 96.40 Very High Very High Very High
Apoptosis 12 93.64 High High
Cancer 129 89.52 High High
Repression 30 84.56 Quite High
Increased Venous Pressure Under Development 182 77.84 Quite High
Recurrence 2 77.64 Quite High
Metastasis 9 76.88 Quite High
Necrosis 61 75.00 Quite High
Atherosclerosis 105 73.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
and rosiglitazone inhibited the effect of the rosiglitazone by reducing CD36 mRNA expression (-59%, 0.41 ± 0.2, p = 0.002) in comparison to basal conditions.
Transcription (expression) of CD36
1) Confidence 0.70 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.08 Pain Relevance 0
Analysis of CD36 mRNA expression using real time PCR
Transcription (expression) of CD36
2) Confidence 0.70 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0 Pain Relevance 0.05
reduced CD36 mRNA expression (-72%, 0.28 ± 0.05, p = 0.002), while rosiglitazone increased CD36 mRNA expression (+46%, 1.46 ± 0.2, p = 0.02).
Transcription (expression) of CD36
3) Confidence 0.70 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.07 Pain Relevance 0
This is in accordance with previous studies showing that products derived from lipid peroxidation induce transcription of CD36 in murine macrophages by activating transcription factors, such as Nrf2 [21,38].
Transcription (transcription) of CD36 in macrophages
4) Confidence 0.70 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.13 Pain Relevance 0.22
M), and the relative quantification of CD36 mRNA expression was carried out by RT-PCR.
Transcription (expression) of CD36
5) Confidence 0.70 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.06 Pain Relevance 0.03
For alpha-2 antagonists, the potency order was: yohimbine greater than idazoxan greater than SK&F-86,466 much greater than benextramine; 3) a description of the impact of benextramine (irreversible alpha-1/alpha-2 antagonist) on human fat cell alpha-2 adrenergic receptors and on human fat cell function; the drug inactivates the alpha-2 adrenergic receptors with a minor impact on beta adrenergic receptors and without noticeable alterations of fat cell function as assessed by preservation of beta adrenergic and Al-adenosine receptor-mediated lipolytic responses; and 4) a definition of the relationship existing between alpha-2 adrenergic receptor occupancy, inhibition of adenylate cyclase activity and antilipolysis with full and partial agonists.
Transcription (description) of fat in fat cell associated with adenocard, antagonist, obesity, agonist and potency
6) Confidence 0.67 Published 1989 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 2566681 Disease Relevance 0.67 Pain Relevance 0.49
monoclonal antibody, adalimumab, independently increases both CD36 membrane expression and mRNA expression.
Transcription (expression) of CD36 associated with adalimumab
7) Confidence 0.52 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.80 Pain Relevance 0.31
and IL1 reduce transcription of fatty acid translocase, homologous to CD36, in hamster adipocytes [31].
Transcription (transcription) of fatty acid translocase in adipocytes associated with obesity
8) Confidence 0.52 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.10 Pain Relevance 0.22
and adalimumab on CD36 mRNA expression, the monocytes were treated with TNF?
Transcription (expression) of CD36 in monocytes associated with adalimumab
9) Confidence 0.52 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0 Pain Relevance 0.39
For calculating relative quantification of CD36 mRNA expression, we used the following procedure: ?
Transcription (expression) of CD36
10) Confidence 0.52 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0 Pain Relevance 0.03
(10 ng/ml) reduced CD36 mRNA expression by 72% (mRNA relative level ± SD: 0.28 ± 0.05, p = 0.002), while adalimumab (1 ?
Transcription (expression) of CD36 associated with adalimumab
11) Confidence 0.52 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0 Pain Relevance 0.32
g/ml) increased CD36 mRNA expression by 96% (1.96 ± 0.2, p = 0.02) in comparison to basal conditions.


Transcription (expression) of CD36
12) Confidence 0.52 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0 Pain Relevance 0.28
reduced CD36 mRNA expression (-72%, 0.28 ± 0.05, p = 0.002), while rosiglitazone increased CD36 mRNA expression (+46%, 1.46 ± 0.2, p = 0.02).
Transcription (expression) of CD36
13) Confidence 0.52 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.07 Pain Relevance 0
Adalimumab independently increases both CD36 membrane expression and mRNA expression.
Transcription (expression) of CD36 associated with adalimumab
14) Confidence 0.52 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0.07 Pain Relevance 0.33
In contrast, adalimumab increases both CD36 membrane expression and mRNA expression.
Transcription (expression) of CD36 associated with adalimumab
15) Confidence 0.52 Published 2007 Journal Arthritis Res Ther Section Abstract Doc Link PMC1906797 Disease Relevance 0.52 Pain Relevance 0.43
Regulation of CD36 mRNA expression by TNF?
Transcription (expression) of CD36
16) Confidence 0.52 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906797 Disease Relevance 0 Pain Relevance 0.39
by enhancement of CD36 gene transcription [74].
Transcription (transcription) of CD36
17) Confidence 0.31 Published 2008 Journal PPAR Research Section Body Doc Link PMC2366048 Disease Relevance 0.98 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox